| P2093 | author name string | Carmel Armon | |
| P2860 | cites work | The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey | Q38341406 |
| | Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial | Q38776278 |
| | Efficacy of Stem Cell Therapy in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis | Q38777893 |
| | Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005-2015 update | Q40957607 |
| | Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice | Q46418017 |
| | How common are ALS plateaus and reversals? | Q30488673 |
| | Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients | Q34699979 |
| | An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis | Q35147590 |
| | Lost in translation: treatment trials in the SOD1 mouse and in human ALS. | Q36735871 |
| | Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? | Q38260277 |
| P921 | main subject | research ethics | Q1132684 |
| | amyotrophic lateral sclerosis | Q206901 |
| | medical ethics | Q237151 |
| P304 | page(s) | 1-6 | |
| P577 | publication date | 2017-09-04 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | Q23928840 |
| P1476 | title | Ethics of clinical research in patients with ALS: is there a risk of exploitation? | |